BioSpace News Archive

BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, is pleased to announce a change of its corporate name to Scinai Immunotherapeutics Ltd.

BioCardia®, Inc. announced a clarification and next steps on its autologous CardiAMP cell therapy programs.

Guangzhou Gloria Biosciences announced that its fully human anti-PD-1 monoclonal antibody, Zimberelimab injection has received marketing approval from the China National Medical Products Administration, as monotherapy for the treatment of recurrent or metastatic cervical cancer patients with positive PD-L1 expression who progressed on or after platinum-based chemotherapy.

Ginkgo Bioworks Holdings, Inc. announced that Anna Marie Wagner, Senior Vice President of Corporate Development, is scheduled to participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13 at 12:55 p.m. ET.

CervoMed Inc. announced the publication online on September 1, 2023, in Neurology®, the medical journal of the American Academy of Neurology, of additional pre-specified analyses of the AscenD-LB Phase 2a clinical trial showing an association between plasma phosphorylated tau at position 181 levels at study entry and patient’s response to neflamapimod in the treatment of dementia with Lewy Bodies.

Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, announced it has exceeded 100 orders of the AVITI System.

TriSalus Life Sciences® Inc., an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, announced that Jodi Devlin has joined the Company as President of TriSalus Therapeutics.

Laborie Medical Technologies, Inc., a leading diagnostic and therapeutic medical technology company, signed a definitive agreement to acquire Urotronic, Inc., a Minnesota-based medical device company pioneering the application of its Optilume® drug-coated balloon technology for use in interventional urology including treating urethral strictures and benign prostatic hyperplasia.

Allay Therapeutics announced the appointment of Nicole Vitullo, venture partner at Arboretum Ventures, to its board of directors.

Nimbus Therapeutics, LLC announced the closing of a $210 million private financing to advance its next wave of tech-enabled small molecule medicines.